Precision Medicine

The Swiss medtech firm reports a massive Q1 sales jump, backed by strong clinical data and a strategic US manufacturing expansion to meet surging demand.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

A new alliance aims to deliver nine vital rare disease therapies to Africa, tackling one of global health's most profound access challenges.

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Backed by Maria Sharapova, new startup Amulet launches a science-first supplement aiming to optimize women's performance throughout their entire cycle.

The insurer is offering at-home defibrillators and health tech, aiming to redefine its role from covering death to extending life. But what does it mean for you?

Constellation Kidney Group's new RCM Intelligence uses AI to help dialysis providers navigate complex billing, reduce costly denials, and improve cash flow.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

New data shows first-in-class drug tegavivint successfully inhibits the Wnt pathway, a driver in 30% of solid tumors, offering hope for tough cancers.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

At a landmark CMS event, Centauri, HealthEx, and Doctronic demo AI-powered apps promising a future where patient data is secure, accessible, and intelligent.

A new natural suppository aims to break the cycle of recurrent yeast infections by supporting the vaginal microbiome, offering hope to millions of women.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.